SOUTH SAN FRANCISCO, Calif., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company has amended the Limited Distribution Agreement, established in December 2011, with Azanta Danmark A/S to include additional territories. The territory originally included the European Union, including the Nordic countries and Switzerland, and Canada. The expanded territories now include Israel and South Korea. The Limited Distribution Agreement provides access to ZYBRESTAT® for the treatment of patients in Europe with anaplastic thyroid cancer (ATC) on a compassionate use basis via a named patient program, managed by Azanta A/S. The Agreement provides a regulatory mechanism to allow healthcare professionals in Europe to prescribe ZYBRESTAT to individual ATC patients while it is still in development. "We are delighted to expand our collaboration with Azanta A/S which has brought ZYBRESTAT to ATC patients in several European countries on a compassionate use basis," said Peter J. Langecker, M.D., Ph.D., Chief Executive Officer of OXiGENE. "We deeply appreciate Azanta's successful implementation of the named patient program, and their commitment to expanding its geographic reach. Their standing as a European specialty pharmaceutical company with specialized technical and regulatory expertise in implementing compassionate use programs, and their dedication to serving the needs of patients suffering with ATC who have no other therapeutic options, make them a valuable partner for OXiGENE." Under the terms of the agreement, OXiGENE provides ZYBRESTAT to Azanta, and Azanta serves as the exclusive distributor for ZYBRESTAT in the specified territory for this purpose. Azanta provides ZYBRESTAT to physicians solely to treat ATC on a compassionate use basis in the territory covered by the agreement until such time as ZYBRESTAT may obtain marketing approval in that territory. OXIGENE and Azanta are cooperating on regulatory activities relating to ZYBRESTAT for the treatment of ATC within the territory.